Share Price and Basic Stock Data
Last Updated: December 11, 2025, 10:35 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Bharat Immunological & Biological Corporation Ltd operates in the pharmaceuticals sector, focusing primarily on immunological and biological products. As of September 2023, the company’s stock price stood at ₹18.5, with a market capitalization of ₹79.8 Cr. Revenue trends have been volatile, with reported sales peaking at ₹26.48 Cr in September 2022, but subsequently declining sharply to ₹0.00 in the last three quarters. This drop raises concerns regarding the company’s operational viability, especially considering that total revenue for the trailing twelve months (TTM) is just ₹8 Cr, a stark contrast to the ₹85 Cr recorded in FY 2021. Such a drastic decline in revenue indicates possible operational challenges or market dynamics that may have adversely affected sales, warranting further scrutiny into their product pipeline and market strategy.
Profitability and Efficiency Metrics
The profitability picture for Bharat Immunological is concerning. The company has reported consecutive net losses, with the latest figure standing at ₹4.92 Cr for September 2023. This translates to a negative net profit margin of -38.23%, showcasing significant challenges in converting revenues into profit. Operating profit margins (OPM) have also been under pressure, with a reported -35.11% in FY 2023. Additionally, the interest coverage ratio (ICR) is alarming at -2.22x, indicating that the company is struggling to meet its interest obligations from operational income. With a return on equity (ROE) of 17.7%, the company appears to be facing an uphill battle to generate returns for shareholders, which is further compounded by a cash conversion cycle of 122 days, reflecting inefficiencies in managing working capital.
Balance Sheet Strength and Financial Ratios
Bharat Immunological’s balance sheet reflects a precarious financial position. The company has total borrowings amounting to ₹74 Cr against reserves of ₹36 Cr, leading to a debt-to-equity ratio of 0.79. This suggests a reliance on debt to finance operations, which could be risky given the current revenue trajectory. The current ratio, a measure of short-term liquidity, is at a low 0.36, indicating potential liquidity issues. Although the book value per share has been reported at ₹20.33, the price-to-book value ratio of 1.09x suggests that the market is pricing in some risk. Investors may want to keep an eye on the company’s ability to manage its liabilities effectively, especially in the light of its declining sales and profitability metrics.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Bharat Immunological shows a significant promoter holding of 59.25%, with the public holding at 40.74%. This concentration of ownership could be a double-edged sword; while it may indicate confidence from the promoters, it can also lead to a lack of diverse viewpoints in strategic decision-making. The number of shareholders has decreased from 38,195 in June 2021 to 35,313 by March 2024, hinting at waning investor interest or confidence in the company. The absence of Foreign Institutional Investors (FIIs) and Domestic Institutional Investors (DIIs) suggests that institutional confidence is lacking, which might make it challenging for the company to attract fresh capital for growth initiatives. This could further impact the stock’s liquidity and price stability.
Outlook, Risks, and Final Insight
The outlook for Bharat Immunological is fraught with challenges. The significant drop in sales and persistent losses raises questions about the company’s operational strategy and market positioning. Investors should be wary of the high debt levels and declining profitability metrics, which may limit financial flexibility. On the flip side, the strong promoter stake could be seen as a positive, indicating that those with the most to lose are committed to the company’s future. However, the absence of institutional backing and the shrinking shareholder base could pose risks for liquidity and future capital raises. As an investor, weighing the potential for recovery against the operational challenges will be crucial. The company needs to demonstrate a clear turnaround strategy to regain investor confidence and stabilize its financial footing.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Bharat Immunological & Biological Corporation Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 141 Cr. | 112 | 239/84.3 | 31.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,246 Cr. | 390 | 479/192 | 87.9 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.0 Cr. | 44.5 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 43.8 Cr. | 29.9 | 31.0/17.0 | 104 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,461.38 Cr | 1,157.79 | 51.81 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
All Competitor Stocks of Bharat Immunological & Biological Corporation Ltd
Quarterly Result
| Metric | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 25.36 | 25.20 | 15.62 | 14.22 | 24.70 | 17.43 | 22.04 | 10.48 | 26.48 | 0.00 | 7.65 | 0.00 | 0.00 |
| Expenses | 29.86 | 27.47 | 31.54 | 13.18 | 28.19 | 16.41 | 25.71 | 15.31 | 28.98 | 4.72 | 11.67 | 4.31 | 4.68 |
| Operating Profit | -4.50 | -2.27 | -15.92 | 1.04 | -3.49 | 1.02 | -3.67 | -4.83 | -2.50 | -4.72 | -4.02 | -4.31 | -4.68 |
| OPM % | -17.74% | -9.01% | -101.92% | 7.31% | -14.13% | 5.85% | -16.65% | -46.09% | -9.44% | -52.55% | |||
| Other Income | 0.14 | 1.20 | 9.08 | 0.25 | 0.22 | 0.12 | 0.59 | 0.14 | 0.32 | 0.10 | 0.49 | 0.10 | 0.16 |
| Interest | 1.17 | 1.30 | 1.22 | 1.16 | 1.23 | 1.54 | 1.68 | 1.58 | 1.74 | 1.67 | 2.06 | 1.72 | 2.09 |
| Depreciation | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.04 | 0.05 | 0.04 | 0.04 | 0.04 | 0.09 | 0.03 | 0.03 |
| Profit before tax | -5.59 | -2.43 | -8.12 | 0.07 | -4.56 | -0.44 | -4.81 | -6.31 | -3.96 | -6.33 | -5.68 | -5.96 | -6.64 |
| Tax % | -30.77% | -21.81% | -19.46% | -2,642.86% | 105.26% | -25.00% | -11.02% | -20.76% | -22.22% | -26.07% | -31.69% | -23.15% | -26.05% |
| Net Profit | -3.87 | -1.89 | -6.53 | 1.93 | -9.36 | -0.33 | -4.28 | -5.00 | -3.08 | -4.68 | -3.88 | -4.59 | -4.92 |
| EPS in Rs | -0.90 | -0.44 | -1.51 | 0.45 | -2.17 | -0.08 | -0.99 | -1.16 | -0.71 | -1.08 | -0.90 | -1.06 | -1.14 |
Last Updated: February 28, 2025, 12:58 pm
Below is a detailed analysis of the quarterly data for Bharat Immunological & Biological Corporation Ltd based on the most recent figures (Sep 2023) and their trends compared to the previous period:
- For Sales, as of Sep 2023, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2023) which recorded 0.00 Cr..
- For Expenses, as of Sep 2023, the value is 4.68 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4.31 Cr. (Jun 2023) to 4.68 Cr., marking an increase of 0.37 Cr..
- For Operating Profit, as of Sep 2023, the value is -4.68 Cr.. The value appears to be declining and may need further review. It has decreased from -4.31 Cr. (Jun 2023) to -4.68 Cr., marking a decrease of 0.37 Cr..
- For OPM %, as of Sep 2023, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Jun 2023) which recorded 0.00%.
- For Other Income, as of Sep 2023, the value is 0.16 Cr.. The value appears strong and on an upward trend. It has increased from 0.10 Cr. (Jun 2023) to 0.16 Cr., marking an increase of 0.06 Cr..
- For Interest, as of Sep 2023, the value is 2.09 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.72 Cr. (Jun 2023) to 2.09 Cr., marking an increase of 0.37 Cr..
- For Depreciation, as of Sep 2023, the value is 0.03 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2023) which recorded 0.03 Cr..
- For Profit before tax, as of Sep 2023, the value is -6.64 Cr.. The value appears to be declining and may need further review. It has decreased from -5.96 Cr. (Jun 2023) to -6.64 Cr., marking a decrease of 0.68 Cr..
- For Tax %, as of Sep 2023, the value is -26.05%. The value appears to be improving (decreasing) as expected. It has decreased from -23.15% (Jun 2023) to -26.05%, marking a decrease of 2.90%.
- For Net Profit, as of Sep 2023, the value is -4.92 Cr.. The value appears to be declining and may need further review. It has decreased from -4.59 Cr. (Jun 2023) to -4.92 Cr., marking a decrease of 0.33 Cr..
- For EPS in Rs, as of Sep 2023, the value is -1.14. The value appears to be declining and may need further review. It has decreased from -1.06 (Jun 2023) to -1.14, marking a decrease of 0.08.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:46 am
| Metric | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 46 | 173 | 203 | 146 | 128 | 124 | 35 | 84 | 67 | 85 | 78 | 45 | 8 |
| Expenses | 41 | 164 | 191 | 143 | 132 | 111 | 43 | 93 | 77 | 106 | 83 | 63 | 25 |
| Operating Profit | 6 | 9 | 12 | 3 | -4 | 13 | -8 | -9 | -10 | -21 | -5 | -18 | -18 |
| OPM % | 12% | 5% | 6% | 2% | -3% | 10% | -23% | -11% | -16% | -24% | -6% | -41% | -232% |
| Other Income | 2 | 1 | 6 | 1 | 1 | 1 | 1 | 4 | 1 | 2 | 1 | 3 | 1 |
| Interest | 0 | 2 | 6 | 1 | 6 | 4 | 1 | 2 | 5 | 5 | 6 | 7 | 8 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 6 | 7 | 11 | 2 | -9 | 9 | -8 | -7 | -14 | -24 | -10 | -23 | -25 |
| Tax % | -111% | 27% | 42% | 26% | -31% | 29% | -46% | -21% | -28% | -25% | -10% | -25% | |
| Net Profit | 13 | 5 | 6 | 2 | -6 | 7 | -4 | -6 | -10 | -18 | -9 | -17 | -18 |
| EPS in Rs | 2.91 | 1.16 | 1.48 | 0.36 | -1.44 | 1.51 | -0.99 | -1.34 | -2.36 | -4.19 | -2.03 | -3.95 | -4.18 |
| Dividend Payout % | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% |
YoY Net Profit Growth
| Year | 2012-2013 | 2013-2014 | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -61.54% | 20.00% | -66.67% | -400.00% | 216.67% | -157.14% | -50.00% | -66.67% | -80.00% | 50.00% | -88.89% |
| Change in YoY Net Profit Growth (%) | 0.00% | 81.54% | -86.67% | -333.33% | 616.67% | -373.81% | 107.14% | -16.67% | -13.33% | 130.00% | -138.89% |
Bharat Immunological & Biological Corporation Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2012-2013 to 2022-2023.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -13% |
| 5 Years: | 5% |
| 3 Years: | -13% |
| TTM: | -90% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -31% |
| TTM: | -42% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | -10% |
| 3 Years: | -9% |
| 1 Year: | -24% |
| Return on Equity | |
|---|---|
| 10 Years: | -12% |
| 5 Years: | -24% |
| 3 Years: | -23% |
| Last Year: | -18% |
Last Updated: September 5, 2025, 2:41 pm
Balance Sheet
Last Updated: July 25, 2025, 1:42 pm
| Month | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 |
| Reserves | -15 | -1 | -3 | -2 | -8 | -1 | -6 | -12 | -23 | -9 | 62 | 45 | 36 |
| Borrowings | 7 | 0 | -1 | -9 | 9 | 0 | 0 | 32 | 3 | 27 | 78 | 70 | 74 |
| Other Liabilities | 45 | 48 | 52 | 48 | 24 | 17 | 16 | 62 | 103 | 43 | 29 | 28 | 35 |
| Total Liabilities | 81 | 90 | 91 | 80 | 68 | 59 | 53 | 125 | 127 | 104 | 213 | 186 | 188 |
| Fixed Assets | 9 | 8 | 7 | 6 | 6 | 5 | 5 | 5 | 4 | 4 | 116 | 115 | 115 |
| CWIP | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 32 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 71 | 82 | 84 | 74 | 63 | 53 | 48 | 120 | 122 | 68 | 97 | 70 | 73 |
| Total Assets | 81 | 90 | 91 | 80 | 68 | 59 | 53 | 125 | 127 | 104 | 213 | 186 | 188 |
Below is a detailed analysis of the balance sheet data for Bharat Immunological & Biological Corporation Ltd based on the most recent figures (Sep 2023) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2023, the value is 43.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2023) which recorded 43.00 Cr..
- For Reserves, as of Sep 2023, the value is 36.00 Cr.. The value appears to be declining and may need further review. It has decreased from 45.00 Cr. (Mar 2023) to 36.00 Cr., marking a decrease of 9.00 Cr..
- For Borrowings, as of Sep 2023, the value is 74.00 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 70.00 Cr. (Mar 2023) to 74.00 Cr., marking an increase of 4.00 Cr..
- For Other Liabilities, as of Sep 2023, the value is 35.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 28.00 Cr. (Mar 2023) to 35.00 Cr., marking an increase of 7.00 Cr..
- For Total Liabilities, as of Sep 2023, the value is 188.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 186.00 Cr. (Mar 2023) to 188.00 Cr., marking an increase of 2.00 Cr..
- For Fixed Assets, as of Sep 2023, the value is 115.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2023) which recorded 115.00 Cr..
- For CWIP, as of Sep 2023, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2023) which recorded 0.00 Cr..
- For Investments, as of Sep 2023, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2023) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2023, the value is 73.00 Cr.. The value appears strong and on an upward trend. It has increased from 70.00 Cr. (Mar 2023) to 73.00 Cr., marking an increase of 3.00 Cr..
- For Total Assets, as of Sep 2023, the value is 188.00 Cr.. The value appears strong and on an upward trend. It has increased from 186.00 Cr. (Mar 2023) to 188.00 Cr., marking an increase of 2.00 Cr..
However, the Borrowings (74.00 Cr.) are higher than the Reserves (36.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -1.00 | 9.00 | 13.00 | 12.00 | -13.00 | 13.00 | -8.00 | -41.00 | -13.00 | -48.00 | -83.00 | -88.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 209 | 2 | 47 | 34 | 37 | 19 | 167 | 318 | 96 | 0 | 5 | 114 |
| Inventory Days | 241 | 87 | 66 | 84 | 77 | 2 | 23 | 67 | 308 | 56 | 202 | 13 |
| Days Payable | 316 | 99 | 70 | 103 | 26 | 1 | 6 | 204 | 259 | 61 | 5 | 4 |
| Cash Conversion Cycle | 134 | -9 | 43 | 16 | 88 | 19 | 185 | 181 | 145 | -5 | 203 | 122 |
| Working Capital Days | -20 | -20 | 21 | 20 | 28 | -19 | 59 | 10 | -108 | -174 | -227 | -549 |
| ROCE % | 20% | 23% | 42% | 9% | -8% | 31% | -18% | -11% | -22% | -46% | -3% | -9% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 23 | Mar 22 | Mar 21 | Mar 20 | Mar 19 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -3.95 | -2.03 | -4.19 | -2.36 | -1.57 |
| Diluted EPS (Rs.) | -3.95 | -2.03 | -4.19 | -2.36 | -1.57 |
| Cash EPS (Rs.) | -3.92 | -1.98 | -4.14 | -2.31 | -1.28 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 20.33 | 24.40 | 7.88 | 4.74 | 7.10 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 20.33 | 24.40 | 7.88 | 4.74 | 7.10 |
| Revenue From Operations / Share (Rs.) | 10.33 | 18.15 | 19.76 | 15.48 | 19.37 |
| PBDIT / Share (Rs.) | -3.63 | -0.89 | -4.45 | -2.14 | -1.18 |
| PBIT / Share (Rs.) | -3.66 | -0.94 | -4.50 | -2.19 | -1.24 |
| PBT / Share (Rs.) | -5.29 | -2.24 | -5.61 | -3.29 | -1.71 |
| Net Profit / Share (Rs.) | -3.95 | -2.03 | -4.19 | -2.36 | -1.34 |
| PBDIT Margin (%) | -35.11 | -4.95 | -22.49 | -13.80 | -6.08 |
| PBIT Margin (%) | -35.44 | -5.22 | -22.76 | -14.15 | -6.41 |
| PBT Margin (%) | -51.22 | -12.35 | -28.36 | -21.25 | -8.81 |
| Net Profit Margin (%) | -38.23 | -11.16 | -21.22 | -15.27 | -6.92 |
| Return on Networth / Equity (%) | -19.42 | -8.30 | -53.20 | -49.87 | -18.88 |
| Return on Capital Employeed (%) | -16.78 | -3.67 | -48.70 | -36.22 | -14.71 |
| Return On Assets (%) | -9.18 | -4.11 | -17.41 | -8.05 | -4.63 |
| Total Debt / Equity (X) | 0.79 | 0.73 | 0.80 | 0.14 | 1.05 |
| Asset Turnover Ratio (%) | 0.22 | 0.49 | 0.73 | 0.53 | 0.93 |
| Current Ratio (X) | 0.36 | 0.64 | 0.52 | 0.92 | 1.12 |
| Quick Ratio (X) | 0.34 | 0.28 | 0.31 | 0.41 | 0.95 |
| Inventory Turnover Ratio (X) | 1.75 | 2.38 | 1.87 | 2.08 | 10.43 |
| Interest Coverage Ratio (X) | -2.22 | -0.69 | -4.02 | -1.95 | -2.54 |
| Interest Coverage Ratio (Post Tax) (X) | -1.42 | -0.56 | -2.79 | -1.15 | -1.89 |
| Enterprise Value (Cr.) | 157.30 | 186.21 | 213.23 | 16.07 | 57.50 |
| EV / Net Operating Revenue (X) | 3.53 | 2.38 | 2.50 | 0.24 | 0.68 |
| EV / EBITDA (X) | -10.04 | -47.96 | -11.11 | -1.74 | -11.29 |
| MarketCap / Net Operating Revenue (X) | 2.15 | 1.55 | 2.30 | 0.37 | 0.39 |
| Price / BV (X) | 1.09 | 1.15 | 5.77 | 1.23 | 1.08 |
| Price / Net Operating Revenue (X) | 2.15 | 1.55 | 2.30 | 0.37 | 0.39 |
| EarningsYield | -0.17 | -0.07 | -0.09 | -0.40 | -0.17 |
After reviewing the key financial ratios for Bharat Immunological & Biological Corporation Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 23, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 22) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 23, the value is -3.95. This value is below the healthy minimum of 5. It has decreased from -2.03 (Mar 22) to -3.95, marking a decrease of 1.92.
- For Diluted EPS (Rs.), as of Mar 23, the value is -3.95. This value is below the healthy minimum of 5. It has decreased from -2.03 (Mar 22) to -3.95, marking a decrease of 1.92.
- For Cash EPS (Rs.), as of Mar 23, the value is -3.92. This value is below the healthy minimum of 3. It has decreased from -1.98 (Mar 22) to -3.92, marking a decrease of 1.94.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 23, the value is 20.33. It has decreased from 24.40 (Mar 22) to 20.33, marking a decrease of 4.07.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 23, the value is 20.33. It has decreased from 24.40 (Mar 22) to 20.33, marking a decrease of 4.07.
- For Revenue From Operations / Share (Rs.), as of Mar 23, the value is 10.33. It has decreased from 18.15 (Mar 22) to 10.33, marking a decrease of 7.82.
- For PBDIT / Share (Rs.), as of Mar 23, the value is -3.63. This value is below the healthy minimum of 2. It has decreased from -0.89 (Mar 22) to -3.63, marking a decrease of 2.74.
- For PBIT / Share (Rs.), as of Mar 23, the value is -3.66. This value is below the healthy minimum of 0. It has decreased from -0.94 (Mar 22) to -3.66, marking a decrease of 2.72.
- For PBT / Share (Rs.), as of Mar 23, the value is -5.29. This value is below the healthy minimum of 0. It has decreased from -2.24 (Mar 22) to -5.29, marking a decrease of 3.05.
- For Net Profit / Share (Rs.), as of Mar 23, the value is -3.95. This value is below the healthy minimum of 2. It has decreased from -2.03 (Mar 22) to -3.95, marking a decrease of 1.92.
- For PBDIT Margin (%), as of Mar 23, the value is -35.11. This value is below the healthy minimum of 10. It has decreased from -4.95 (Mar 22) to -35.11, marking a decrease of 30.16.
- For PBIT Margin (%), as of Mar 23, the value is -35.44. This value is below the healthy minimum of 10. It has decreased from -5.22 (Mar 22) to -35.44, marking a decrease of 30.22.
- For PBT Margin (%), as of Mar 23, the value is -51.22. This value is below the healthy minimum of 10. It has decreased from -12.35 (Mar 22) to -51.22, marking a decrease of 38.87.
- For Net Profit Margin (%), as of Mar 23, the value is -38.23. This value is below the healthy minimum of 5. It has decreased from -11.16 (Mar 22) to -38.23, marking a decrease of 27.07.
- For Return on Networth / Equity (%), as of Mar 23, the value is -19.42. This value is below the healthy minimum of 15. It has decreased from -8.30 (Mar 22) to -19.42, marking a decrease of 11.12.
- For Return on Capital Employeed (%), as of Mar 23, the value is -16.78. This value is below the healthy minimum of 10. It has decreased from -3.67 (Mar 22) to -16.78, marking a decrease of 13.11.
- For Return On Assets (%), as of Mar 23, the value is -9.18. This value is below the healthy minimum of 5. It has decreased from -4.11 (Mar 22) to -9.18, marking a decrease of 5.07.
- For Total Debt / Equity (X), as of Mar 23, the value is 0.79. This value is within the healthy range. It has increased from 0.73 (Mar 22) to 0.79, marking an increase of 0.06.
- For Asset Turnover Ratio (%), as of Mar 23, the value is 0.22. It has decreased from 0.49 (Mar 22) to 0.22, marking a decrease of 0.27.
- For Current Ratio (X), as of Mar 23, the value is 0.36. This value is below the healthy minimum of 1.5. It has decreased from 0.64 (Mar 22) to 0.36, marking a decrease of 0.28.
- For Quick Ratio (X), as of Mar 23, the value is 0.34. This value is below the healthy minimum of 1. It has increased from 0.28 (Mar 22) to 0.34, marking an increase of 0.06.
- For Inventory Turnover Ratio (X), as of Mar 23, the value is 1.75. This value is below the healthy minimum of 4. It has decreased from 2.38 (Mar 22) to 1.75, marking a decrease of 0.63.
- For Interest Coverage Ratio (X), as of Mar 23, the value is -2.22. This value is below the healthy minimum of 3. It has decreased from -0.69 (Mar 22) to -2.22, marking a decrease of 1.53.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 23, the value is -1.42. This value is below the healthy minimum of 3. It has decreased from -0.56 (Mar 22) to -1.42, marking a decrease of 0.86.
- For Enterprise Value (Cr.), as of Mar 23, the value is 157.30. It has decreased from 186.21 (Mar 22) to 157.30, marking a decrease of 28.91.
- For EV / Net Operating Revenue (X), as of Mar 23, the value is 3.53. This value exceeds the healthy maximum of 3. It has increased from 2.38 (Mar 22) to 3.53, marking an increase of 1.15.
- For EV / EBITDA (X), as of Mar 23, the value is -10.04. This value is below the healthy minimum of 5. It has increased from -47.96 (Mar 22) to -10.04, marking an increase of 37.92.
- For MarketCap / Net Operating Revenue (X), as of Mar 23, the value is 2.15. This value is within the healthy range. It has increased from 1.55 (Mar 22) to 2.15, marking an increase of 0.60.
- For Price / BV (X), as of Mar 23, the value is 1.09. This value is within the healthy range. It has decreased from 1.15 (Mar 22) to 1.09, marking a decrease of 0.06.
- For Price / Net Operating Revenue (X), as of Mar 23, the value is 2.15. This value is within the healthy range. It has increased from 1.55 (Mar 22) to 2.15, marking an increase of 0.60.
- For EarningsYield, as of Mar 23, the value is -0.17. This value is below the healthy minimum of 5. It has decreased from -0.07 (Mar 22) to -0.17, marking a decrease of 0.10.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Bharat Immunological & Biological Corporation Ltd:
- Net Profit Margin: -38.23%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -16.78% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -19.42% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -1.42
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.34
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 51.81)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.79
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -38.23%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | BIBCOL, OPV Plant, Village Chola, Bulandshahar Dist Uttar Pradesh 203203 | complianceofficer_bibcol@yahoo.in http://www.bibcol.com |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Y K Gupta | Chairman |
| Dr. Sanjay Kumar Mishra | Managing Director |
| Dr. Alka Sharma | Director |
| Dr. Mohd Aslam | Director |
| Mr. Roshan Lal | Director |
| Dr. Sudhanshu Vrati | Director |
| Dr. Madhu Dikshit | Director |
FAQ
What is the intrinsic value of Bharat Immunological & Biological Corporation Ltd?
Bharat Immunological & Biological Corporation Ltd's intrinsic value (as of 11 December 2025) is 39.43 which is 104.30% higher the current market price of 19.30, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 83.3 Cr. market cap, FY2025-2026 high/low of 35.9/18.0, reserves of ₹36 Cr, and liabilities of 188 Cr.
What is the Market Cap of Bharat Immunological & Biological Corporation Ltd?
The Market Cap of Bharat Immunological & Biological Corporation Ltd is 83.3 Cr..
What is the current Stock Price of Bharat Immunological & Biological Corporation Ltd as on 11 December 2025?
The current stock price of Bharat Immunological & Biological Corporation Ltd as on 11 December 2025 is 19.3.
What is the High / Low of Bharat Immunological & Biological Corporation Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Bharat Immunological & Biological Corporation Ltd stocks is 35.9/18.0.
What is the Stock P/E of Bharat Immunological & Biological Corporation Ltd?
The Stock P/E of Bharat Immunological & Biological Corporation Ltd is .
What is the Book Value of Bharat Immunological & Biological Corporation Ltd?
The Book Value of Bharat Immunological & Biological Corporation Ltd is 18.2.
What is the Dividend Yield of Bharat Immunological & Biological Corporation Ltd?
The Dividend Yield of Bharat Immunological & Biological Corporation Ltd is 0.00 %.
What is the ROCE of Bharat Immunological & Biological Corporation Ltd?
The ROCE of Bharat Immunological & Biological Corporation Ltd is 9.27 %.
What is the ROE of Bharat Immunological & Biological Corporation Ltd?
The ROE of Bharat Immunological & Biological Corporation Ltd is 17.7 %.
What is the Face Value of Bharat Immunological & Biological Corporation Ltd?
The Face Value of Bharat Immunological & Biological Corporation Ltd is 10.0.